HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.

Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.

Auraflora is transforming oral health with natural innovation, while Herman Science is fighting human and insider threat ...

You’ve been losing weight, and the finish line is in sight. Or maybe you’ve already hit your goal weight. What do you do when you get there? Should you keep taking your oral weight loss medication?

In the latest trading session, Zoetis (ZTS) closed at $151.19, marking a +2.59% move from the previous day. The stock's ...

Investors interested in stocks from the Gaming sector have probably already heard of Light & Wonder (LNW) and DraftKings ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

Define Ventures, a digital health venture capital fund, is training a new generation of healthcare AI leaders through its AI Fellows program—a program designed to shape startups focused o | The VC ...

Kohl’s came into July with 53 million shares shorted, or about 47% of shares outstanding, according to FactSet. That’s ...

The Zacks Consensus Estimate for SNOW’s fiscal 2026 earnings is pegged at $1.06 per share, unchanged over the past 30 days.

Detailed price information for Lululemon Athletica (LULU-Q) from The Globe and Mail including charting and trades.